MX2024003804A - Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih. - Google Patents

Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih.

Info

Publication number
MX2024003804A
MX2024003804A MX2024003804A MX2024003804A MX2024003804A MX 2024003804 A MX2024003804 A MX 2024003804A MX 2024003804 A MX2024003804 A MX 2024003804A MX 2024003804 A MX2024003804 A MX 2024003804A MX 2024003804 A MX2024003804 A MX 2024003804A
Authority
MX
Mexico
Prior art keywords
antigen binding
polypeptide complexes
polypeptides
hiv
methods
Prior art date
Application number
MX2024003804A
Other languages
English (en)
Spanish (es)
Inventor
Gary J Nabel
Ling Xu
Zhi-Yong Yang
Ronnie Rong Wei
Original Assignee
Modex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modex Therapeutics Inc filed Critical Modex Therapeutics Inc
Publication of MX2024003804A publication Critical patent/MX2024003804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024003804A 2021-09-29 2022-09-28 Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih. MX2024003804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163249722P 2021-09-29 2021-09-29
PCT/US2022/077203 WO2023056315A1 (en) 2021-09-29 2022-09-28 Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv

Publications (1)

Publication Number Publication Date
MX2024003804A true MX2024003804A (es) 2024-06-11

Family

ID=85783606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003804A MX2024003804A (es) 2021-09-29 2022-09-28 Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih.

Country Status (13)

Country Link
US (1) US20250197481A1 (enExample)
EP (1) EP4408892A4 (enExample)
JP (1) JP2024537827A (enExample)
KR (1) KR20240099226A9 (enExample)
CN (1) CN118660907A (enExample)
AR (1) AR127176A1 (enExample)
AU (1) AU2022357501A1 (enExample)
CA (1) CA3232365A1 (enExample)
CL (1) CL2024000890A1 (enExample)
IL (1) IL311762A (enExample)
MX (1) MX2024003804A (enExample)
TW (1) TW202325744A (enExample)
WO (1) WO2023056315A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
WO2025162460A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 一种轭合化合物及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX353382B (es) * 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
RS62437B1 (sr) * 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
AU2019372673A1 (en) * 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白

Also Published As

Publication number Publication date
JP2024537827A (ja) 2024-10-16
KR20240099226A9 (ko) 2025-12-10
CN118660907A (zh) 2024-09-17
IL311762A (en) 2024-05-01
AU2022357501A1 (en) 2024-04-18
EP4408892A4 (en) 2025-11-19
CA3232365A1 (en) 2023-04-06
WO2023056315A1 (en) 2023-04-06
KR20240099226A (ko) 2024-06-28
AR127176A1 (es) 2023-12-27
EP4408892A1 (en) 2024-08-07
US20250197481A1 (en) 2025-06-19
CL2024000890A1 (es) 2024-10-11
TW202325744A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2024003808A (es) Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos.
EA202192103A1 (ru) Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
MX2024006968A (es) Anticuerpos cdh17 y metodos de tratamiento del cancer.
MX2024007393A (es) Complejos polipeptidicos de union a antigeno activados condicionalmente y metodos de uso de los mismos.
MX2024003804A (es) Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos en el vih.
MX2023004598A (es) Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
MX2023001256A (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos.
MX2024015643A (es) Polipéptidos de unión al antígeno contra el coronavirus 2 del síndrome respiratorio agudo grave (anti-sars-cov-2), complejos de polipéptidos y métodos de uso de estos
MX2025013732A (es) Anticuerpos de dominio unico modificados
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
WO2022032004A3 (en) Anti-claudin 18.2 multi-specific antibodies and uses thereof
WO2025010376A3 (en) Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins
WO2023060137A3 (en) Methods and compositions comprising b7-h3 binding polypeptides
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma
MX2024007120A (es) Complejos polipeptidicos de union a antigeno que contienen dominios extracelulares de ligandos de la superfamilia del factor de necrosis tumoral (tnfsf).
MX2025015364A (es) Proteinas de union al antigeno contra el peptido antigenico b2 asociado al melanoma expresado en tumores (mageb2)
WO2022067269A3 (en) Antibodies against sars-cov-2
MX2023007583A (es) Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.
MX2025010673A (es) Proteinas de union a antigeno anti-cd25 y usos de las mismas
MX2025007907A (es) Proteinas de union al antigeno anti-tnfr2 y sus usos
MX2025001874A (es) Anticuerpos y receptores de antigenos quimericos especificos para el ligando 3 similar a delta (dll3)
WO2024007013A3 (en) Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof